QIAGEN launches QIAstat-Dx in Japan with respiratory panel for syndromic testing
24 Abril 2023 - 5:05PM
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today
that its QIAstat-Dx syndromic testing solution is expected to be
available soon for use in Japan with a SARS-CoV-2 Respiratory Panel
that can detect more than 20 pathogens from a single patient
sample.
The availability in Japan is expected in
mid-2023 after decisions on reimbursement levels and comes as the
next step after the recent granting of IVD approval for the test.
The entry into Japan will add to more than 100 countries worldwide
– including the United States, as well as countries across Europe
and other areas of the world – where QIAstat-Dx solutions and
various syndromic tests to diagnose diseases are available.
“We are pleased to announce upcoming
availability of our QIAstat-Dx SARS-CoV-2 Respiratory Panel in
Japan, which enhances our commitment to improving healthcare around
the world,” said Jean-Pascal Viola, Senior Vice President and Head
of the Molecular Diagnostics Business Area at QIAGEN. “QIAstat-Dx
enables easy operation with less labor compared to standard
individual PCR assays for each pathogen and provides powerful
support for medical workers in respiratory medicine, pediatrics and
emergency medicine.”
The system is designed to operate in
laboratories and employs cost-efficient, single-use cartridges with
all reagents on board and built-in sample processing.
Using multiplex real-time PCR, QIAstat-Dx
detects and differentiates between multiple pathogens. QIAstat-Dx
is the only syndromic testing system to provide Ct values and easy
access to amplification curves. Access to this supplementary data
provides additional insight, allowing for better-informed decisions
for patients.
With more than 3,500 systems installed worldwide
at the end of 2022, QIAstat-Dx is used in hospitals, laboratories
and clinics as an easy-to-use solution for reliable diagnosis of
various diseases. The first group of panels available are for the
detection of respiratory or gastrointestinal pathogens or for
distinguishing between meningitis and encephalitis
infections.[1]
QIAstat-Dx is available in two formats: The
QIAstat-Dx version that brings together up to four Analytical
Modules into one integrated system, and the QIAstat-Dx Rise
high-capacity version that provides comprehensive testing for up to
160 tests per day using eight Analytical Modules.1
QIAstat-Dx connects to the QIAsphere cloud-based
platform that provides remote monitoring of the instruments and
test status, allowing customers to receive push notifications on
their personal devices. It can monitor an unlimited number of
instruments across different hospitals or satellite labs, reducing
system downtime and enabling fast and accurate syndromic testing.
Connectivity is achieved through the Qbase hub, which can be
connected to QIAstat-Dx in minimal time through hospitals’ LAN or
Wi-Fi network, ensuring sensitive patient data remains within the
hospital network.
QIAsphere also allows users to view and export
reports on real-time local, regional and global epidemiology data
through QIAsphere Insights to support epidemiological surveillance.
Further, with the recent release of a medical reference app for
QIAstat-Dx users, the Pathogen Guide, QIAstat-Dx is poised as a
leader in digital diagnostic technology for customers around the
world.
More information on QIAstat-Dx can be found
here:
https://www.qiagen.com/us/applications/syndromic-testing About
QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare), Applied Testing (primarily
forensics), Pharma (pharma and biotech companies) and Academia
(life sciences research). As of December 31, 2022, QIAGEN
employed approximately 6,200 people in over 35 locations worldwide.
Further information can be found at http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, collaborations
markets, strategy or operating results, including without
limitation its expected adjusted net sales and adjusted diluted
earnings results, are forward-looking, such statements are based on
current expectations and assumptions that involve a number of
uncertainties and risks. Such uncertainties and risks include, but
are not limited to, risks associated with management of growth and
international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission
(SEC).
Source: QIAGEN N.V.
Category: Corporate
[1] Product availability may differ from country to country
based on regulations and approvals.
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Eltrop
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024